Nanomedicine Tumor Targeting
Abstract: Nanomedicines are extensively explored for cancer therapy. By delivering drug molecules more efficiently to pathological sites and by attenuating their accumulation in healthy organs and tissues, nanomedicine formulations aim to improve the balance between drug efficacy and toxicity. More than 20 cancer nanomedicines are approved for clinical use, and hundreds of formulations are in (pre) clinical development. Over the years, several key pitfalls have been identified as bottlenecks in nanomedicine tumor targeting and translation. These go beyond materials‐ and production‐related issues, and particularly also encompass biological barriers and pathophysiological heterogeneity. In this manuscript, the author describes the most important principles, progress, and products in nanomedicine tumor targeting, delineates key current problems and challenges, and discuss the most promising future prospects to create clinical impact.
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Nanomedicine Tumor Targeting ; day:12 ; month:04 ; year:2024 ; extent:20
Advanced materials ; (12.04.2024) (gesamt 20)
- Urheber
- DOI
-
10.1002/adma.202312169
- URN
-
urn:nbn:de:101:1-2024041314384903456254
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
Ähnliche Objekte (12)
Nanomedicine Tumor Targeting
![Evaluation of the role of PP2Cα [PP2Calpha] in growth regulation, in cellular stress signaling and in tumorigenesis](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Evaluation of the role of PP2Cα [PP2Calpha] in growth regulation, in cellular stress signaling and in tumorigenesis
Challenges in nanomedicine clinical translation
Challenges in nanomedicine clinical translation
Nanomedicine formulations for combination therapies
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
High-resolution 3D visualization of nanomedicine distribution in tumors
Auger emitter based endogenous therapy with an Olaparib derivative in triple negative breast cancer
Microbubbles for ultrasound-mediated drug delivery
Temperature-sensitive polymers to promote heat-triggered drug release from liposomes: Towards bypassing EPR
Bridging the gap between lab and clinic for nanodiagnostics
Nonspherical microbubbles for ultrasound-mediated drug delivery
Nanomedicine Tumor Targeting
Evaluation of the role of PP2Cα [PP2Calpha] in growth regulation, in cellular stress signaling and in tumorigenesis
Challenges in nanomedicine clinical translation
Challenges in nanomedicine clinical translation
Nanomedicine formulations for combination therapies
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
High-resolution 3D visualization of nanomedicine distribution in tumors
Auger emitter based endogenous therapy with an Olaparib derivative in triple negative breast cancer
Microbubbles for ultrasound-mediated drug delivery
Temperature-sensitive polymers to promote heat-triggered drug release from liposomes: Towards bypassing EPR
Bridging the gap between lab and clinic for nanodiagnostics
Nonspherical microbubbles for ultrasound-mediated drug delivery
Nanomedicine Tumor Targeting
Evaluation of the role of PP2Cα [PP2Calpha] in growth regulation, in cellular stress signaling and in tumorigenesis
Challenges in nanomedicine clinical translation
Challenges in nanomedicine clinical translation
Nanomedicine formulations for combination therapies
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
High-resolution 3D visualization of nanomedicine distribution in tumors
Auger emitter based endogenous therapy with an Olaparib derivative in triple negative breast cancer
Microbubbles for ultrasound-mediated drug delivery
Temperature-sensitive polymers to promote heat-triggered drug release from liposomes: Towards bypassing EPR
Bridging the gap between lab and clinic for nanodiagnostics